Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15398724 | 0.89 | — | — | |
| Nonivamide SCHEMBL992015 | 0.85 | CYP1A2 (0.75) | TRPV1 | |
| SCHEMBL12049620 | 0.85 | — | — | |
| SCHEMBL6304141 | 0.85 | DUSP3 (0.54) | TRPV1 | |
| SCHEMBL6302420 | 0.85 | TRPV1 (0.56) | TRPV1 | |
| SCHEMBL30884017 | 0.85 | PTPN7 (0.69) | TRPV1 | |
| SCHEMBL2849365 | 0.85 | PTPN7 (0.69) | TRPV1 | |
| SCHEMBL29212726 | 0.85 | ALDH1A1 (0.71) | — | |
| SCHEMBL29212711 | 0.84 | DUSP3 (0.72) | — | |
| SCHEMBL29212730 | 0.84 | TRPV1 (0.69) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197867-A1 | NEURAL CONTROL OF ADAPTIVE IMMUNITY | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH | 2024-06-20 | — | — | US | claimed |
| WO-2022182940-A1 | NEURAL CONTROL OF ADAPTIVE IMMUNITY | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2022-09-01 | — | — | WO | claimed |
| EP-3970723-A1 | AMINOINDANE COMPOUNDS FOR USE IN TREATING UROLOGICAL PAIN | Asana BioSciences, LLC (US) | 2022-03-23 | — | — | EP | claimed |
| US-20220016046-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-01-20 | — | — | US | claimed |
| US-20210290561-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2021-09-23 | — | — | US | claimed |
| EP-3363437-B1 | AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN | ENDO PHARMACEUTICALS SOLUTIONS (US) | 2021-07-28 | — | — | EP | claimed |
| US-20210186906-A1 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-06-24 | — | — | US | claimed |
| CN-107540599-B | Aminoindane compounds and their use to treat pain | 阿萨纳生物科技有限责任公司 | 2021-06-04 | — | — | CN | claimed |
| EP-3363437-A1 | AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN | Endo Pharmaceuticals Solutions Inc. (US) | 2018-08-22 | — | — | EP | claimed |
| EP-2675787-B1 | AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN | ENDO PHARMACEUTICALS INC (US) | 2018-03-28 | — | — | EP | claimed |
| EP-2451944-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | President and Fellows of Harvard College (US) | 2012-05-16 | — | — | EP | claimed |
| JP-2011513484-A | — | — | 2011-04-28 | — | — | JP | claimed |
| WO-2011006073-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-01-13 | — | — | WO | claimed |
| EP-2271329-A2 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | President and Fellows of Harvard College (US) | 2011-01-12 | — | — | EP | claimed |
| US-20100311678-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER AND MODULATING SIGNAL TRANSDUCTION AND METABOLISM PATHWAYS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2010-12-09 | — | — | US | claimed |
| US-20100099772-A1 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-22 | — | — | US | claimed |
| EP-2101819-A2 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-09-23 | — | — | EP | claimed |
| WO-2009114139-A2 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-09-17 | — | — | WO | claimed |
| WO-2009045504-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER AND MODULATING SIGNAL TRANSDUCTION AND METABOLISM PATHWAYS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-04-09 | — | — | WO | claimed |
| WO-2008063603-A2 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2008-05-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311678-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER AND MODULATING SIGNAL TRANSDUCTION AND METABOLISM PATHWAYS | PC, PCK2, PDK1 | TRPV1 3963/4885 |
| US-20100099772-A1 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | TRPV1, TRPV2, TRPV3 | TRPV1 1/4885 |
| US-20240197867-A1 | NEURAL CONTROL OF ADAPTIVE IMMUNITY | TRPV1, TRPA1, TRPV2 | TRPV1 1/4885 |
| US-20210290561-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | TRPV1, CACNA1B, ORAI1 | TRPV1 1/4885 |
| US-20220016046-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CACNA1B, TRPV1, ORAI1 | TRPV1 2/4885 |
| US-20210186906-A1 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | TRPV1, TRPV2, TRPV3 | TRPV1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.